View Older Stories

Aug 25, 2026 04:01PM Ascendis to present 2-year navepegritide trial data at ISDS 2026

Aug 19, 2026 05:29AM BMO Capital Starts Ascendis Pharma (ASND) at Outperform

Aug 13, 2026 04:08PM Ascendis Pharma (ASND) PT Raised to $360 at Citi

Aug 13, 2026 04:03PM Ascendis Pharma (ASND) PT Raised to $333 at Jefferies

Aug 13, 2026 07:41AM Ascendis Pharma (ASND) Tops Q2 EPS by 132c

Aug 6, 2026 08:01AM Ascendis reports COACH trial Week 78 data and Yuviwel uptake

Jul 14, 2026 06:03AM Ascendis Pharma (ASND) PT Raised to $306 at BofA Securities

Jun 15, 2026 07:07AM Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND)

Jun 9, 2026 06:51AM Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND)

Jun 3, 2026 04:30AM Analysts see a buying opportunity in this pharma stock

May 7, 2026 07:40AM Ascendis Pharma (ASND) Tops Q1 EPS by 9c

May 6, 2026 04:01PM Ascendis reports sustained growth in achondroplasia trial subgroup

Apr 15, 2026 04:36PM Ascendis Pharma (ASND) PT Raised to $292 at BofA Securities

Apr 8, 2026 08:02AM Ascendis shows combination therapy benefits in achondroplasia trial

Apr 6, 2026 04:01PM Ascendis launches YUVIWEL for achondroplasia in US market

Apr 1, 2026 07:03AM Ascendis Pharma (ASND) Reiterated at Overweight by Cantor Fitzgerald After Model Update

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 17, 2026 08:32AM Ascendis Pharma reports positive Turner syndrome trial results for TransCon hGH

Mar 5, 2026 04:18PM Ascendis Pharma (ASND) PT Raised to $262 at BofA Securities

Mar 4, 2026 03:22PM Ascendis Pharma (ASND) PT Raised to $332 at Stifel

Mar 2, 2026 03:49PM Ascendis Pharma (ASND) PT Raised to $275 at RBC Capital

Mar 2, 2026 03:21PM Ascendis Pharma (ASND) PT Raised to $295 at Leerink Partners

Mar 2, 2026 12:56PM Morgan Stanley on Ascendis Pharma (ASND): 'we view Yuviwel’s approval as a positive inflection for Ascendis'

Mar 2, 2026 10:59AM Ascendis Pharma (ASND) PT Raised to $260 at Wolfe Research

Mar 2, 2026 10:38AM Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)

Mar 2, 2026 10:03AM Ascendis Pharma (ASND) PT Raised to $324 at Evercore ISI

Mar 2, 2026 09:19AM Stifel Reiterates Buy Rating on Ascendis Pharma (ASND) as Yuviwel Approved for Achondroplasia

Mar 2, 2026 04:55AM Ascendis Pharma (ASND) PT Raised to $255 at Goldman Sachs

Feb 23, 2026 08:58AM RBC Capital: 'KOL Sees Ascendis Pharma's (ASND) Commercial Momentum Continuing Steadily From Here'

Feb 12, 2026 01:54PM Ascendis Pharma (ASND) PT Raised to $300 at Cantor Fitzgerald

Feb 12, 2026 10:03AM Ascendis Pharma (ASND) PT Raised to $325 at Stifel Following Q4 Results

Feb 12, 2026 07:41AM BioMarin (BMRN), Ascendis (ASND) Trade Lower Following Competitor Data

Feb 11, 2026 04:01PM Ascendis Pharma (ASND) Misses Q4 EPS by 40c

Jan 22, 2026 11:56AM Ascendis Pharma (ASND) Strength Tied to Unconfirmed M&A Chatter

Jan 20, 2026 05:30AM Ascendis Pharma (ASND) PT Raised to $250 at RBC Capital

Jan 12, 2026 08:26AM Ascendis (ASND) Reiterated at Buy by Stifel on Yprvipath Beat

Jan 12, 2026 08:18AM Ascendis Pharma (ASND) Reiterated at Overweight by Cantor Fitzgerald

Jan 9, 2026 07:10AM Ascendis Pharma (ASND) Reiterated at Buy by Stifel After Release of June Study Data

Jan 8, 2026 04:04PM Ascendis reports positive 52-week trial data for achondroplasia treatment

Jan 8, 2026 08:49AM 4Q25/2026 Biotech Earnings Preview: RBC

Jan 7, 2026 09:13AM TD Cowen on Ascendis Pharma (ASND): 'Physician Survey Shows Smooth Sailing For Yorvipath'

Dec 12, 2025 03:22PM Ascendis Pharma (ASND) Gains Appear to be Tied to Unconfirmed M&A Chatter

Nov 26, 2025 07:00AM Ascendis Pharma's (ASND) PDUFA Extension a Minor Issue - Cantor Fitzgerald

Nov 26, 2025 06:48AM Ascendis Pharma's (ASND) PDUFA Disclosure Removes Near-Term Stock Upside - Stifel

Nov 24, 2025 08:53AM TD Cowen Reiterates Buy Rating on Ascendis Pharma (ASND)

Nov 17, 2025 04:10PM Wolfe Research Starts Ascendis Pharma (ASND) at Outperform

Nov 17, 2025 04:01PM Ascendis Pharma publishes pivotal trial results for achondroplasia drug

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 13, 2025 06:55AM Ascendis Pharma (ASND) Looks at Decreased FY2025-26 Revenues - Cantor Fitzgerald

Nov 13, 2025 04:04AM Goldman Sachs on Ascendis Pharma (ASND): 'in transition to profitability'

View Older Stories